Marinomed Biotech AG is a biopharmaceutical development company focusing on the development of innovative therapies based on patent protected technology platforms. Products against respiratory viruses derived from the proprietary MAVIREX© platform are marketed with renowned partners in a growing number of... Show more »
Marinomed Biotech AG is a biopharmaceutical development company focusing on the development of innovative therapies based on patent protected technology platforms. Products against respiratory viruses derived from the proprietary MAVIREX© platform are marketed with renowned partners in a growing number of countries around the globe.
The new MARINOSOLV® platform enables novel stable aqueous formulations of hardly soluble compounds such as corticosteroids, allowing a faster onset of action and a better bioavailability. The MARINOSOLV® technology is not limited to a specific compound and has the potential to facilitate delivery of any compound with solubility issues.
Marinomed Biotech AG is a spin-off from the Veterinary University Vienna and is located in Vienna, Austria.
The patent protected MARINOSOLV® platform enables novel stable aqueous formulations of hardly soluble compounds such as corticosteroids, allowing a faster onset of action and a better bioavailability.
The MARINOSOLV® technology is not limited to a specific compound and has the potential to facilitate delivery of any compound... Show more »
The patent protected MARINOSOLV® platform enables novel stable aqueous formulations of hardly soluble compounds such as corticosteroids, allowing a faster onset of action and a better bioavailability.
The MARINOSOLV® technology is not limited to a specific compound and has the potential to facilitate delivery of any compound with solubility issues.
MARINOSOLV® is superior when sensitive tissues such as those of the eye, nose, lung or others are targeted. Marinomed has extensive experience in developing and commercialization of products for respiratory and ocular disorders
The patent protected MARINOSOLV® platform enables novel stable aqueous formulations of hardly soluble compounds such as corticosteroids, allowing a faster onset of action and a better bioavailability.
The MARINOSOLV® technology is not limited to a specific compound and has the potential to facilitate delivery of any compound... Show more »
The patent protected MARINOSOLV® platform enables novel stable aqueous formulations of hardly soluble compounds such as corticosteroids, allowing a faster onset of action and a better bioavailability.
The MARINOSOLV® technology is not limited to a specific compound and has the potential to facilitate delivery of any compound with solubility issues.
MARINOSOLV® is superior when sensitive tissues such as those of the eye, nose, lung or others are targeted. Marinomed has extensive experience in developing and commercialization of products for respiratory and ocular disorders
Formulation Services
Formulation Services
Drug Discovery & Development Services
Drug Discovery & Development Services
Biology Services
Biology Services
Microbiology Services
Microbiology Services
Virology Services
Virology Services
Project and Process Management Services
Project and Process Management Services
Marinomed Biotech AG has not received any reviews.
Marinomed Biotech AG has not received any endorsements.